Latest Advances in Lung Cancer Research

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Dr. Suresh Ramalingam, a top cancer expert at Emory University, urges community oncologists to prioritize biomarker testing and lung cancer screening to ensure every patient benefits from the latest treatment breakthroughs — because advances only matter if all patients can access them.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.

Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

Oncologists have discovered that difficulties treating and managing the most common type of lung cancer, adenocarcinoma or non-small cell lung cancer, is related to a protein called agrin.

Researchers at Johns Hopkins Medicine have developed an innovative computer model that could significantly improve immunotherapy outcomes for lung cancer patients.

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.

New blood test using ctDNA methylation biomarkers shows promise for early lung cancer detection, potentially improving treatment outcomes for patients.